Fig. 2
From: FGF15 promotes hepatic NPC1L1 degradation in lithogenic diet-fed mice
EZE treatment decreased bile cholesterol saturation in HFCD-fed mNPC1L1hepatic-OE mice. The WT and mNPC1L1hepatic-OE mice were fed with 8-week HFCD and LD, with or without EZE treatment prior to the indicated experiments. In mNPC1L1hepatic-OE mice: A Biliary cholesterol (a), bile acids (b), phospholipid (c) and (d) CSIs in a-d panels. B Cholesterol (a) and triglyceride (b) from liver tissues. C Cholesterol (a) and triglyceride (b) from plasma. In WT mice: D Biliary cholesterol (a), bile acids (b), phospholipid (c) and (d) CSIs in a-d panels. E Cholesterol (a) and triglyceride (b) from liver tissues. F Cholesterol (a) and triglyceride (b) from plasma. Mann-Whitney U-test for data with non-normal distribution and Student’s t-test for normal distributions. *P < 0.05, **P < 0.01, ns no significance. EZE, ezetimibe; HFCD, high fat-cholesterol diet; CSI, cholesterol saturation index